NEWARK, Calif., Sept. 3, 2015 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced that Harold Van Wart, Ph.D., President and Chief Executive Officer, will present a corporate update at the Rodman & Renshaw 17th Annual Global Investment Conference being held in New York City on September 8-10.
Rodman & Renshaw 17th Annual Global Investment Conference
|Date:||Thursday, September 10|
|Time:||2:35pm Eastern Time|
|Place:||St. Regis Hotel, New York, NY|
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate, CymaBay's lead product candidate, has shown two therapeutic actions in a single drug in multiple Phase 2 gout studies. In gout patients, arhalofenate is intended to prevent painful flares in joints while at the same time promoting excretion of uric acid by the kidney, thereby addressing both the signs and symptoms of gout and the hyperuricemia that is the root cause of the disease. CymaBay's second product candidate, MBX-8025 is a potent, selective, orally active PPARδ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. The FDA has granted MBX-8025 an orphan drug designation for the treatment of homozygous familial hypercholesterolemia (HoFH) and CymaBay has initiated a pilot study of MBX-8025 in patients with HoFH.
For additional information about CymaBay visit www.cymabay.com